|Bid||236.12 x 3100|
|Ask||236.40 x 1100|
|Day's Range||229.53 - 239.70|
|52 Week Range||76.59 - 331.68|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 08, 2021 - Nov. 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||264.20|
Moderna Presdient Stephen Hoge joins Yahoo Finance to discuss the latest infomration about Moderna's COVID-19 vaccine.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Read more to find out why we think Novavax (NASDAQ: NVAX), Sorrento Therapeutics (NASDAQ: SRNE), and InMode (NASDAQ: INMD) will close out 2021 with a bang. Taylor Carmichael (Novavax): Novavax stock has already doubled this year, running from $112 back in January to $233 this week. Right now, Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation.